OTLK
$1.23
Outlook Therapeutics
$.02
1.65%
OTLK
Earnings Whisper ®
N/A
4th Quarter September 2020
Consensus:  ($0.10)
Revenue:  $0.65 Mil
Thursday
Dec 17
8:05 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when OTLK reports earnings?
Beat
Meet
Miss

Where is OTLK's stock price going from here?
Up
Flat
Down
Stock chart of OTLK
Analysts
Summary of analysts' recommendations for OTLK
Score
Grade
Pivots
Resistance
$1.36
$1.33
$1.28

$1.24

Support
$1.19
$1.16
$1.11
Tweet
Growth
Description
Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as Oncobiologics Inc., is based in Cranbury, United States.